Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesObstetrics/GynecologyBlue Cross Blue Shield OK Cervical Screening Polic…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB002

    Cervical Cancer Screening

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLAB002 alerts

    Get alerted when Policy CPCPLAB002 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines reimbursement and laboratory coding criteria for cervical cancer screening tests (Pap cytology, high-risk HPV testing, and co-testing) for BCBS Oklahoma members and provider billing expectations.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyCervical Cancer Screening
    Policy CodePolicy CPCPLAB002
    Change TypeMaterial updates to codes and immunocompromised screening frequency
    Effective DateJan 15, 2025
    Last ReviewNov 19, 2024
    Next Review Date
    Key ActionVerify member eligibility and submit accurate documentation using valid HIPAA-approved codes; confirm plan-specific prior authorization where applicable.
    SourceLink
    POLICY UPDATE CHANGES

    Added new CPT code 87626 effective 01/01/2025.

    Reimbursement criterion for immunocompromised individuals updated to allow annual cytology for individuals of all ages and co-testing every 3 years for those 30 and older.

    Added nucleic acid testing for HPV-16 and HPV-18 for HPV positive / cytology negative individuals.

    Clarified recommendations for individuals over 65: routine screening not reimbursable if adequate prior screening documented.

    Added CPT code 0502U to the code list.

    ≥3consecutive negative Pap smears required
    ≤2consecutive negative HPV tests (10y; recent within 5y)
    3yPap smear reimbursable interval (21-29 yrs)
    3-5yOptions for 30-65 yrs
    All agesAnnual cytology (immunocompromised)

    Medically Necessary and Not Medically Necessary Criteria

    Medically necessary coverage criteria

    Covered when meeting the specified age- and risk-based criteria:

    Immunocompromised screening: For immunocompromised or immunosuppressed individuals, ANY one of the following may be reimbursable: (a) annual cervical cytology testing for individuals of all ages; (b) co-testing (cervical cytology and high-risk HPV testing) once every 3 years for individuals 30 years of age or older.

    Immunocompromised definition implied by guideline references.

    Age 21-29: Individuals 21 to 29 years: cervical cancer screening once every 3 years using conventional or liquid based Papanicolaou (Pap) smears may be reimbursable.age 21-29
    Age 30-65: Individuals 30 to 65 years: ANY one of the following may be reimbursable: (a) conventional or liquid based Pap smear once every 3 years; (b) primary high-risk HPV testing once every 5 years; (c) co-testing (cytology with concurrent high-risk HPV testing) once every 5 years.age 30-65
    Age >65 high-risk: Individuals over 65 who are considered high-risk (history of high-grade precancerous lesion or cervical cancer, or in utero exposure to diethylstilbestrol/DES) may be reimbursable at the frequencies described for ages 30-65.age >65 and high-risk
    HPV positive / cytology negative reflex testing: For individuals who are HPV positive and cytology negative, nucleic acid testing for high-risk strains HPV-16 and HPV-18 may be reimbursable.HPV+ and cytology-
    Younger high-risk or prior abnormal: For individuals 65 years of age or younger, annual cervical cancer screening by Pap smear or HPV testing may be reimbursable if there was a previous abnormal cytology result and/or positive HPV, or other high-risk status (e.g., organ transplant, DES exposure).<=65 with risk factors or prior abnormal

    Cervical cancer screening for individuals less than 21 years of age is not reimbursable except as specified elsewhere in this policy. Claims for routine screening in this age group will be denied unless a specific exception described in other reimbursement criteria applies.

    Cervical cancer screening is not reimbursable for individuals who have undergone surgical removal of the uterus and cervix and who have no history of cervical cancer or pre‑cancer. This exclusion applies at any age.

    Routine cervical cancer screening for individuals over 65 years of age who are not considered high‑risk is not reimbursable when an adequate screening history is documented. Adequate screening history is defined as either (a) three consecutive negative Pap smears, or (b) two consecutive negative HPV tests within 10 years with the most recent test within 5 years.

    Procedure, Laboratory Codes and Definitions

    Procedure and lab CPT/HCPCS codes listedmixed
    87623
    87624
    87625
    87626
    88141
    88142
    88143
    88147
    88148
    88150
    1–10 of 32
    1/4
    Adequate screening history — definition
    Adequate screening history (definition)Three consecutive negative Pap smears OR two consecutive negative high-risk HPV tests within 10 years, with the most recent test occurring within 5 years.
    Time window (Pap)Three consecutive negative Pap smears within the 10-year period before stopping routine screening.
    Time window (HPV)Two consecutive negative high-risk HPV tests within 10 years, with the most recent HPV test within 5 years before stopping routine screening.
    ApplicabilityUsed to determine eligibility to discontinue routine cervical cancer screening for individuals over 65 who are not high-risk.

    Billing, Documentation, and Denial Risk Guidance

    Documentation Required

    Claims documentation and coding requirements

    Providers are responsible for submission of accurate documentation of services performed. Providers must submit claims using HIPAA-approved code sets and follow industry standard coding guidelines (e.g., Uniform Billing Editor, AMA CPT, HCPCS, ICD-10-CM/PCS, NDCs, DRG rules, CMS NCCI). Claims are subject to code-edit protocols and clinical review; upon request providers should supply supporting documentation.

    • Use valid code combinations from HIPAA-approved code sets.
    • Follow industry coding guidance (CPT, HCPCS, ICD-10, NDC, CMS NCCI/CCI, DRG).
    • Be prepared to provide additional documentation upon request.
    Billing Rule

    Code listing and prior authorization note

    Clinical Background and Rationale

    Cervical cancer screening uses cytology (Papanicolaou/Pap smear), high‑risk HPV testing, or both (co‑testing) to detect precancerous changes. This policy aligns reimbursement with age‑ and risk‑based guideline recommendations: for immunocompromised individuals, annual cytology or co‑testing every 3 years for those ≥30 may be reimbursable; for ages 21–29, Pap smear every 3 years is reimbursable; for ages 30–65, any one of Pap every 3 years, primary high‑risk HPV testing every 5 years, or co‑testing every 5 years may be reimbursable. For HPV positive / cytology negative results, reflex nucleic acid testing for high‑risk strains HPV‑16 and HPV‑18 may be reimbursable. National guideline bodies inform these intervals and the policy’s risk‑stratified approach.

    Terms and Policy-Specific Definitions

    Definition — 'individual(s)'
    Termindividual(s)
    DefinitionIn this policy, 'individual(s)' specifically refers to persons with a cervix.
    ContextUsed throughout the reimbursement criteria to specify the population eligible for cervical cancer screening policies.
    Definition — adequate screening history
    Adequate screening history (concise)Either three consecutive negative Pap smears OR two consecutive negative HPV tests within 10 years, with the most recent test within 5 years.
    PurposeDetermines when routine screening may be ceased for individuals over 65 who are not high-risk.
    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyCervical Cancer Screening
    Policy CodePolicy CPCPLAB002
    Change TypeMaterial updates to codes and immunocompromised screening frequency
    Effective DateJan 15, 2025
    Last ReviewNov 19, 2024
    Next Review Date
    Key ActionVerify member eligibility and submit accurate documentation using valid HIPAA-approved codes; confirm plan-specific prior authorization where applicable.
    SourceLink
    On This Page
    Medically Necessary and Not Medically Necessary CriteriaProcedure, Laboratory Codes and DefinitionsBilling, Documentation, and Denial Risk GuidanceClinical Background and RationaleTerms and Policy-Specific Definitions

    The codes listed are provided for reference only. Inclusion does not guarantee coverage or payment; verify member benefits, applicable plan documents, and provider contract terms. Prior authorization may be required by some plans — check eligibility and prior authorization rules before rendering services.

    • Reference procedure codes: 87623, 87624, 87625, 87626, 88141, 88142, 88143, 88147, 88148, 88150, 88152, 88153, 88164, 88165, 88166, 88167, 88174, 88175, 0500T, 0502U, G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, G0476, P3000, P3001, Q0091
    Denial Risk

    Denial triggers

    Denial risk increases when services fall outside stated reimbursement criteria — for example, routine cervical cancer screening for individuals over 65 who are not high risk with an adequate screening history, screening after hysterectomy when there is no history of cervical cancer or pre-cancer, or screening for individuals under 21 outside specified exceptions. Claims lacking adequate clinical history or documentation to demonstrate medical necessity may be denied.

    • Routine screening not reimbursable for >65 with adequate screening history (see definitions in policy).
    • Screening not reimbursable after total hysterectomy without prior cervical cancer/pre-cancer.
    • Screening for individuals <21 generally not reimbursable unless specific exceptions apply.
    • Insufficient documentation of medical necessity or history may trigger denial.
    Evidence window
    Most recent qualifying test must have occurred within 5 years of cessation decision.
    ConsequenceIf documented, routine cervical cancer screening for individuals over 65 who are not high-risk is not reimbursable.